Nomogram Based on Systemic Immune-Inflammation Index to Predict Overall Survival in Gastric Cancer Patients

Table 1

Clinicopathological characteristics of patients with gastric cancer in the primary cohort and the validation cohort.

Characteristic	Primary cohort ()		Validation cohort ()
	No. of patients	%	No. of patients	%
Sex
Male	471	68.5	131	75.3
Female	217	31.5	43	24.7
Age
≤60	463	67.3	103	59.2
>60	225	32.7	71	40.8
Tumor location
Upper	106	15.4	28	16.1
Middle	267	38.8	53	30.5
Lower	315	45.8	93	53.4
Histological grade
Well or moderately differentiated	367	53.3	100	57.5
Poorly or not differentiated	321	46.7	74	42.5
Lauren type
Diffuse	115	16.7	34	19.5
Intestinal	328	47.7	75	43.1
Mixed	245	35.6	65	37.4
Tumor size
≤5	316	45.9	72	41.4
>5	372	54.1	102	58.6
Lymphovascular invasion
No	483	70.2	111	63.8
Yes	205	29.8	63	36.2
Perineural invasion
No	392	57.0	122	29.9
Yes	296	43.0	52	70.1
TNM stage (AJCC, 8th)
I	183	26.6	43	24.7
II	215	31.3	88	50.6
III	290	42.2	43	24.7
Adjuvant chemotherapy
No	267	38.8	62	35.6
Yes	421	61.2	112	64.4